49 results about "Growth Factor Gene" patented technology

Atherosclerotic plaque and blood vessels may be stabilized by directing vibrational energy, typically ultrasonic energy, into the adjacent blood vessel wall. Application of the vibrational energy, optionally in combination with growth factors, growth factor genes, or other substances which enhance growth instability of a fibrotic cap over the plaque, will reduce the risk of rupture of unstable plaque and inhibit the conversion of stable plaque into unstable plaque.

The invention discloses a tissue engineered bone compound which comprises porous perforated between aperture artificial bone bracket and mesenchymal stem cells implanted in hole and transfected with vascular endothelial growth factor gene. The invention also discloses the application of the tissue engineered bone compound as material for bone defect repair. The inventive tissue engineered bone compound can make seed cell exert osteogenesis, express and secrete VEGF, thereby promoting vasal formation and growth, providing material basis for new bone formation, in favor of neogenesis of vascularized tissue engineered bone tissue, improving effect for repairing bone defect.

This invention relates to compounds, compositions, and methods useful for modulating placental growth factor (e.g., PGF-1 or PlGF-1, PGF-2 or PlGF-2, and / or PGF-3 or PlGF-3) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of placental growth factor gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of placental growth factor genes.

The invention belongs to the field of biotechnology, especially the detection of gene mutation. More specifically, the invention discloses 9 groups of primers for detection of 41 mutation of a human epidermal growth factor EGFR gene and a detection method by using the primers.

The invention discloses a construction method and a purpose of recombinant lactobacillus acidophilus expressing pig epidermal growth factors. Primers containing specific enzyme cutting sites are designed according to disclosed gene sequences and expression vector plasmid characteristics of the pig epidermal growth factors; pig lower jaw glandular tissues are taken as the material, a segment containing pig epidermal growth factor genes is obtained through a reverse transcription-polymerase chain reaction (RT-PCR), and the segment is connected with a lactobacillus expression vector plasmid pMG36e to obtain a recombinant plasmid pMG36e-egf, the recombinant plasmid is placed into lactobacillus acidophilus with an electrotransformation method to obtain the recombinant lactobacillus acidophilus expressing the pig epidermal growth factors, expression is performed under the induction of nisin, and correct expression of target genes is proved through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot. The recombinant lactobacillus acidophilus is used for preventing diarrhea occurrence, improving intestinal tract health of pigs and promoting growth performance.

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

The present invention provides one kind of pig's epidermal growth factor gene with the nucleotide sequence shown in SEQ ID No. 1 of the sequence list. The present invention provides also the gene engineering bacterium C32 containing 14 copies of the gene, and the gene engineering bacterium has high pEGF expressing amount, simple purifying process and low production cost. The present invention makes it possible to produce pig's epidermal growth factor gene in industrial scale.

The present invention provides a composite fiber which comprises an alginate fiber, a polymer material, an antibacterial agent, and a plasmid encoding growth factor-gene. The present invention also provides a wound dressing, wherein the wound dressing comprises a composite fiber as described above. The composite fibers prepared according to the present invention are capable of releasing the antibacterial agent and the growth factor gene, not only to reduce microorganism growth, but also to secrete growth factors in a wound site through transfection, thereby promoting wound healing.

The invention discloses an artificial porcine epidermal growth factor eukaryotic expression vector and a preparation method and brewers yeast engineering bacteria thereof. A porcine epidermal growth factor gene is artificially synthesized according to the preference of brewers yeast to a porcine epidermal growth factor codon, and is shown as SEQ ID NO. 1 in a sequence table. The invention further provides a brewers yeast expression vector containing the gene and engineering bacteria with secretory expression of the gene, and further provides a method for obtaining the engineering bacteria. The artificial porcine epidermal growth factor gene has preference to the brewers yeast; the engineering bacteria of the gene have a brewers yeast signal peptide which is favorable for the secretory expression of the porcine epidermal growth factor and is induced by raffinose which can be used as feed instead of methanol during expressing the porcine epidermal growth factor; and the engineering bacteria and the expressed product can be directly used as feed without being purified and extracted, so that the cost and growth period of the porcine epidermal growth factor as feed are greatly reduced, and the application of the porcine epidermal growth factor in the feed industry becomes possible.

Belonging to the technical field of genetic engineering, the invention provides a method for producing human insulin-like growth factor-1 (human insulin-like growth factor 1, hIGF-1) by the vegetable oil ribosomal protein expression system. In the method of the invention, human insulin-like growth factor-1 gene is designed and synthesized according to preference of vegetable codon and the human insulin-like growth factor-1 gene is fused with oil body protein gene, thus constructing a vegetable expression vector which expresses promoter drive by seed specificity; the vector is transformed into a receptor plant and human insulin-like growth factor-1 with biological activity is expressed in a transformed plant seed. The insulin-like growth factor-1 obtained by the method of the invention can be applied to treat IGF-1 insufficiency and deletion of growth hormone (GH) found in children or other clinical and lab researches.

Tissue engineered constructs including a matrix and cells transfected with a gene for a growth factor. The constructs may be implanted into a tissue site, where the growth factor gene enhances a metabolic function furthering integration of the construct in the tissue site. If the matrix is biodegradable, the metabolic result may include resorption of the matrix and replacement with tissue synthesized at least in part by the transfected cells.

This invention provides alternative bone implants that have high bioadaptability and enable rapid bone regeneration. Specifically, this invention relates to implants consisting of a bioadaptable material comprising cells transfected with growth factor genes. Such implants are produced by inoculating bone-marrow-derived cells transfected with the genes of vascular endothelial growth factors (VEGF) into a bioadaptable material, such as porous ceramics, and culturing them.

This invention provides compositions and methods to diagnose and treat polycystic disorders by inhibiting the biological activity of a gene now correlated with appearance of this disorder. By way of illustrative only, the Tissue Growth Factor-alpha (TGF-α) gene is an example of such a gene. Also provided by this invention are compositions and methods to treat or ameliorate abnormal cystic lesions and diseases associated with the formation of cysts in tissue. The methods and compositions treat and ameliorate pathological cyst formation in tissue by inhibiting or augmenting gene expression or the biological activity the gene expression product, or its receptor.

A canine hepatocyte growth factor gene and a 15 base pairs-deleted gene thereof encode a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4 and a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids and having a canine hepatocyte growth factor activity. The canine hepatocyte growth factor and the 5 amino acids-deleted canine hepatocyte growth factor are useful for the treatment of liver diseases, kidney diseases, lung diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.

This invention relates to compounds, compositions, and methods useful for modulating placental growth factor (e.g., PGF-1 or PlGF-1, PGF-2 or PlGF-2, and / or PGF-3 or PlGF-3) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of placental growth factor gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of placental growth factor genes.

The invention provides an encoding gene of a recombinant insulin-like growth factor, lactobacillus containing the encoding gene and application of the lactobacillus, and belongs to the field of bio-genetic engineering. The insulin-like growth factor is a multifunctional cell proliferation regulation factor, has important acceleration in differentiation, proliferation, and growth and development of cells, but has the problems of insufficient throughout, high price, required purification of product, difficult drug administration and the like just as most of genetic engineering drugs. In order to obtain a lot of recombinant insulin-like growth factors, recombinant insulin-like growth factor genes optimized by codons are subjected to heterologous expression by adopting a lactobacillus expression system, and the recombinant lactobacillus is utilized as a living bacteria agent or a feed additive to enhance the nonspecific immunity of a pig.

The invention discloses a brassica napobrassica growth regulatory factor gene GRF2 and an application thereof. A base sequence of the gene is a nucleotide sequence represented by SEQ ID NO:1; or a gene sequence of another crop, wherein the gene sequence has no less than 70% homology with that represented by SEQ ID NO:1; or a mutant allele or a derivative obtained after one or more nucleotides areprocessed through addition, substitution, insertion or deletion. As a result of researches, the expression level of the gene in brassica napobrassica high-oil parents and high-oil mixture crops is higher than that in low-oil parents and low-oil mixture crops. A transgene result obtained by using arabidopsis thaliana as an acceptor verified that, with the over-expression of the gene, arabidopsis thaliana oil content is improved, and a 1000-seed weight of arabidopsis thaliana is increased. The invention also provides an application of brassica napobrassica growth regulatory factor gene BnGRF2 in improving the 1000-seed weight and oil content of plants such as arabidopsis thaliana. Therefore, the gene has good application prospect in oil-yield seed breeding of brassica napobrassica and otheroil crops.

The invention discloses a Keratinocyte growth factor gene, vectors with the Keratinocyte growth factor gene and an application of the Keratinocyte growth factor gene, and belongs to the technical field of genetic engineering. The invention is characterized by comprising a gene segment which codes a Keratinocyte growth factor and has a nucleotide sequence shown in the formula SEQ ID NO.1, expression vectors with the gene segment and a system of expressing the Keratinocyte growth factor in pichia yeast through the expression vectors. Through the system of expressing a Keratinocyte growth factorin pichia yeast, the advantages of low cost, short cycle, easy realization of a technical scheme, and favorable expression level reaching to an industrialized production level are realized.

The invention discloses a fetus liver matrix cell strain for expressing alkaline fibroblastic growth factors. The fetus liver matrix cell strain of the invention is a recombinant fetus liver matrix cell strain carried with alkaline fibroblastic growth factor genes. By experimental verification, recombinant fetus liver matrix cells of the invention can highly efficiently produce secretory alkaline fibroblastic growth factors, and embryonic stem cell proliferation of human beings and embryonic stem cell drying can be maintained under the condition of no exogenous alkaline fibroblastic growth factors by taking the cells as feeder layer cells for in vitro culture of embryonic stem cells of human beings. The recombinant fetus liver matrix cells of the invention and a construction method thereof provide appropriate microenvironment for researches in the aspects of construction of a low-cost (reduction of introduction of exogenous alkaline fibroblastic growth factors), safe and highly efficient (capable of replacing odontogenic zooblast as the feeder layer cells) in vitro culture system of the embryonic stem cells of human beings and development and differentiation of hematopoietic cells, and the invention has wide application prospect.

The invention relates to a cell growth factor gene drug for preventing and / or treating acute stress-related gastrointestinal injury, and use of HIF-1 alpha and KGF genes in preparing drugs for preventing and / or treating acute stress-related gastrointestinal injury diseases. The invention also relates to a pharmaceutical composition comprising HIF-1 alpha and KGF. The growth factor gene drug provided by the invention can beneficially prevent and / or treat acute stress-related gastrointestinal injury diseases.

The invention discloses a recombinant bacillus calmette-guerin vaccine secreting bacteria resuscitation somatomedin and application thereof. The recombinant bacillus calmette-guerin vaccine uses the bacillus calmette-guerin vaccine as host cell. An exogenous expression vector carrying out transfection on the host cell is an expression vector comprising a bacteria resuscitation somatomedin genetic fragment. The recombinant bacillus calmette-guerin vaccine can continuously secrete Rpf factors with bioactivity and can induce a humoral immunity response level and a cellular immune response level. An antibody which is generated by aiming at the exogenous Rpf can interdict the stimulating effect of the Rpf to MTB. The level of inducing IFN-gamma of the recombinant bacillus calmette-guerin vaccine is superior to that of BCG. The recombinant bacillus calmette-guerin vaccine is applied to preparation of a preventive immunity vaccine for MTB infection and / or MTB inapparent infection.

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

The invention provides functions of imaginal disk growth factors (IDGF) and an application of dsRNA of the imaginal disk growth factors. The imaginal disk growth factors can assist insects to resist germ invasion. When the imaginal disk growth factors keep silent by the dsRNA, the resistibility of the insects is reduced until the insects die. After the imaginal disk growth factor gene of black cutworms is subjected to cloning and sequencing, the obtained sequence is as shown in SEQID NO:1; on the base of the obtained sequence, a fragment of which the sequence is as shown in SEQID NO:2 is selected and is used for synthesis of double-strand RNA(dsRNA); and after the dsRNA is injected into the body cavities of the insects, the phenomena that the resistibility is reduced, the insects are susceptible to germs and melanism appears are presented in the development process of the insects, and the mortality rate is greatly raised. The imaginal disk growth factors disclosed by the invention provide a new target for pest control.

The invention relates to a composition for improving cerebral neurotrophic function. The composition comprises, by weight, 91.1-99.8% of asparagus extract, 0-2.4% of phosphatidylserine, 0-2.4% of fungal extract, 0.09-1.6% of theanine and 0.09-2.0% of gamma-aminobutyric acid. The asparagus extract is solid powder or liquid, and refers to the extract, with asparagus saponin content not less than 0.3g / 100g, extracted from one or multiple of asparagus stems, leaves or leftovers; the fungal extract refers to the extract from one or multiple of shiitake mushroom, glossy ganoderma, hericium erinaceus, pleurotus cornucopiae and pleurotus eryngii; extraction solvents of the asparagus extract and the fungal extract both refer to water or mixture of ethyl alcohol and water. The composition can promote growth of the brain derived neurotrphic factor by increasing content of hippocampus acetyl choline, improve mechanisms such as neurotrophic growth factor gene expression, and play a role in improving the cerebral neurotrophic function.

The invention relates to biology and medicine fields, concretely, relates to application of liver cell growth factor in preventing and treating tissue accretion. The invention inserts human hepatocyte growth factor full-length coding region cDNA into plasmid carrier (pc DNA 3 or p UDK or others), or into adenovirus carrier (such as Ad5 or gutless adenovirus) to obtain recombinant plasmid or recombinant adenovirus of the human hepatocyte growth factor gene. The recombinant plasmid or recombinant adenovirus can prevent and cure postoperative intestinal adhesion or pelvic cavity adhesion or other tissue adhesion by being locally painted on abdominal cavity or pelvic cavity. Thus, the recombinant plasmid or recombinant adenovirus carrying the human hepatocyte growth factor gene has excellent application prospect on prevent-curing or treatment for postoperative tissue adhesion.

The invention relates to a platelet-derived growth factor modifying gene suitable for silkworm expression and an expression vector and application thereof. The nucleotide sequence of the platelet-derived growth factor modifying gene is shown as 7th-399th bots of SEQ ID NO.1, encoded amino acid is shown as SEQ ID NO.2, an expression box is formed by the platelet-derived growth factor modifying gene, a secretory sericin 1 gene promoter and a secretory sericin 1 gene terminator, the expression is enhanced by an enhanser hr3, and meanwhile a piggyBac transposition arm and a fluorescent screening marker gene are connected to form an expression system, a recombined platelet-derived growth factor is efficiently expressed by the expression system in a silkworm silk gland, and the expression systemhas biological activity and can be used for producing recombined platelet-derived growth factors in a large scale and has an excellent market prospect.

The invention discloses a method for obtaining a polyclonal antibody of a sheep independent growth factor 1B, which comprises the following steps: performing PCR (polymerase chain reaction) amplification on a sheep independent growth factor 1B gene by using a designed specific primer GFI-1, thus obtaining a CDS sequence thereof; performing enzyme cutting by using a specific primer GFI-2, and constructing a prokaryotic expression vector, thus obtaining the prokaryotic expression vector pET32a-GFI1B; performing target gene induced expression on the prokaryotic expression vector pET32a-GFI1B, thus obtaining a sheep independent growth factor 1B protein; purifying the sheep independent growth factor 1B protein to 85% or above; immunizing the purified sheep independent growth factor 1B protein onto an animal, collecting whole blood one week after the last immunization, and separating the blood serum; and purifying the blood serum, thus obtaining the polyclonal antibody of the target sheep independent growth factor 1B gene.

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

The invention provides application of a human hepatocyte growth factor gene in eczema treatment and a microneedle medical instrument. The human hepatocyte growth factor gene is constructed into an eukaryotic expression vector, a virus vector and a gene expression cassette or minicircle DNA (Deoxyribose Nucleic Acid), and can obviously play a role in resisting eczema and related symptoms after being locally introduced subcutaneously by adopting a microneedle or injection mode and the like. Therefore, the human hepatocyte growth factor gene has an extremely good application prospect in the aspect of eczema treatment, and especially in the form of a microneedle instrument, not only can the eczema symptom be inhibited, but also the side effect is small.

The invention discloses a recombinant transgenic vector carrying a human insulin-like growth factor-I and a use thereof. The recombinant transgenic vector comprises an exogenous human insulin-like growth factor(IGF)-I gene, a promoter and an enhancer element; a transposons for constructing the recombinant transgenic vector is a piggyback transposons; and the promoter is fibroin heavy chain protein promoter. The recombinant transgenic vector also comprises corresponding DNA sequence of the downstream signal peptide of the fibroin heavy chain protein promoter and the sequence of a bombyx mori fibroin light-chain gene fib-LpolyA signal site. Transgenic bombyx mori producing IGF-I, which is prepared by using the recombinant transgenic vector, has a higher IGF-I expression level and can ensurethe safety of the exogenous gene and rhabdovirus.